Survodutide is a weekly injection from Boehringer Ingelheim and Zealand Pharma that hits two targets at once: the GLP-1 receptor and the glucagon receptor.
The GLP-1 half is familiar. It is the same pathway as semaglutide, reducing appetite and slowing stomach emptying. The glucagon half is the interesting part. Glucagon is usually thought of as the hormone that raises blood sugar, which sounds like the opposite of what you want. But it also increases the rate at which your body burns energy, and it pushes the liver to break down stored fat.
So instead of only reducing how much you eat, the design tries to raise how much you burn at the same time. That dual approach has drawn particular attention for fatty liver disease, where the liver effects matter as much as the weight.
It is not approved anywhere yet and has not been filed for approval. Analysts expect a possible obesity approval around 2027.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
No reviews yet. Be the first.
AOD9604 is a fragment of human growth hormone — specifically the last 15 amino acids at one end of the molecul…
Cagrilintide is a long acting version of amylin, a hormone your pancreas releases alongside insulin whenever y…
CJC-1295 is a synthetic version of a hormone your body already produces called GHRH — growth hormone releasing…
Survodutide reported full Phase 3 obesity results in April 2026. At the highest dose tested it produced up to 16.6 percent average weight loss at 76 weeks, against 3.2 percent for placebo, and met both of its main goals. More than 85 percent of participants lost at least 5 percent of their weight.
Placed against its competitors, that result sits in an awkward middle. It beats semaglutide at the standard 2.4 mg dose, which produced about 14.9 percent in its own trial. It falls short of tirzepatide at roughly 20.9 percent, of high dose semaglutide, and of CagriSema.
The usual caution about comparing across trials applies, since these studies enrolled different people over different timeframes. But a gap of several percentage points is large enough to matter commercially.
Where survodutide may find its place is the liver. The glucagon side of the molecule acts directly on liver fat, and the drug is being developed for fatty liver disease alongside obesity. If that pans out, it could end up mattering more as a liver treatment than as a weight loss drug.